| abstract |
A pharmaceutical composition comprising a sodium-glucose transporter substrate (SGLT-1) as an active ingredient, formulated with pharmaceutically acceptable carriers, in which the SGLT-1 substrate is present at a concentration of about 0.3 mM to about 3.0 mM, wherein the SGLT-1 substrate is glucose or a non-metabolizable glucose analog that is selected from the group consisting of α-methyl-D-glucopyranoside (AMG), 3-O-methylglucose (3- OMG), deoxy-D-glucose and α-methyl-D-glucose, which further comprises an NSP4 protein, NSP4 peptide or NSP4 toxoid as the active ingredient. |